首页> 外文期刊>Alimentary pharmacology & therapeutics. >Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
【24h】

Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

机译:结肠镜检查法定量检测免疫化学粪便潜血试验和敏感愈创木脂试验以检测重要结直肠肿瘤的相对效率。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The guaiac faecal occult blood test (G-FOBT), HemoccultSENSA, is sensitive for significant neoplasms [colorectal cancer (CRC), advanced adenomatous polyps (AAP)], but faulted by non-specificity for human haemoglobin (Hb). Quantified, Hb- specific, immunochemical faecal occult blood tests (I-FOBT) are now used. AIMS: To (i) compare I-FOBT and G-FOBT efficacy in identifying significant neoplasms and colonoscopy needs for positive tests and (ii) examine number of I-FOBTs needed and test threshold to use for equivalent or better sensitivity than G-FOBT and fewest colonoscopies for positive tests. METHODS: Three daily G-FOBTs and I-FOBTs were collected and analysed in 330 patients scheduled for colonoscopy. RESULTS: Colonoscopy found significant neoplasms in 32 patients, 6 CRC, 26 AAP. G-FOBT, sensitivity and specificity were 53.1% (17 neoplasms) and 59.4%, resulting in 8.1 colonoscopieseoplasm. One I-FOBT having >or=50 ngHb/mL of buffer provided equivalent sensitivity but 94.0% specificity, resulting in 2.1 colonoscopieseoplasm. By analysing the higher of two I-FOBTs at 50 ngHb/mL threshold, sensitivity increased to 68.8% (22 neoplasms, P = 0.063), specificity fell to 91.9% (P < 0.001), but still required 2.1 colonoscopieseoplasm. CONCLUSIONS: In this population, quantified I-FOBT had significantly better specificity than G-FOBT for significant neoplasms, reducing the number of colonoscopies neededeoplasm detected. Results depend on the number of I-FOBTs performed and the chosen development threshold.
机译:背景:愈创木脂粪潜血试验(G-FOBT)HemoccultSENSA对重要的肿瘤[结肠直肠癌(CRC),晚期腺瘤性息肉(AAP)]敏感,但由于对人血红蛋白(Hb)的非特异性而存在缺陷。现在使用定量的Hb特异性免疫化学粪便潜血试验(I-FOBT)。目的:(i)比较I-FOBT和G-FOBT在确定重要的肿瘤和结肠镜检查对阳性测试的需求中的功效,以及(ii)检查与I-FOBT和G-FOBT等效或更好的敏感性所需的I-FOBT数量和测试阈值最少的结肠镜检查阳性。方法:收集330例行结肠镜检查的患者,每天分析其3次G-FOBT和I-FOBT。结果:结肠镜检查发现32例患者中有明显的肿瘤,其中6例为CRC,26例为AAP。 G-FOBT,敏感性和特异性分别为53.1%(17例肿瘤)和59.4%,导致8.1例结肠镜检查/肿瘤。一种缓冲液浓度大于或等于50 ngHb / mL的I-FOBT提供了相同的灵敏度,但特异性为94.0%,从而产生了2.1个结肠镜检查/肿瘤。通过在50 ngHb / mL阈值下分析两个I-FOBT中的较高者,敏感性提高到68.8%(22个肿瘤,P = 0.063),特异性下降到91.9%(P <0.001),但仍需要2.1个结肠镜检查/肿瘤。结论:在该人群中,定量的I-FOBT对重要的肿瘤具有比G-FOBT明显更好的特异性,从而减少了所需的结肠镜检查/检出的肿瘤数量。结果取决于执行的I-FOBT数量和选择的开发阈值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号